Interviews
The Belgian biotech is closing its CAR-T division and pivoting to a new de-risked business development model, with the blessing of long-term investor, Gilead.
Fund IV exclusively targets company creation and early-stage investing across the UK and the US.
The company is getting ready for multiple cancer drug launches, potentially including anti-PD-L1/VEGF pumitamig. Chief commercial officer Annemarie Hanekamp spoke to Scrip.
The company’s chief operating officer and next CEO Karen Massey talked with Scrip about the rise of Vyvgart and how the Dutch biotech is planning for the next phase of growth.
The pharma titan candidly speaks about the M&A landscape, high R&D costs and the potential of AI as the industry gets set to navigate a host of existing and new challenges.
Europe produces world-class science, but lags behind other regions in translating discoveries into groundbreaking innovations that create jobs and drive economic growth. A new fund from the owners of Novo Nordisk hopes to change that.
The CEO of Inno Medicine tells Scrip the Chinese company has developed a novel active-targeting nano-liposomal formulation to reverse coronary atherosclerosis plaque, which has yielded positive proof-of-concept Phase Ib/IIa results.
Servier has deepened its AI-enabled collaborations with a deal potentially worth over €1bn with Iktos to accelerate small-molecule drug discovery for undisclosed targets in oncology and neurology.
Alteogen’s new CEO shares his dynamic five years with the Korean biotech which led to its transformation into a global commercial stage biotech with a potential stable revenue base.
Watch this video to learn more about Asymchem’s expanding R&D capabilities at its European hub in Sandwich, England.
GSK builds up its arsenal of antibody-drug conjugates, while Oxford BioTherapeutics adds another pharma heavyweight to its expansive roster of partners.
To develop bispecific, dual-payload antibody-drug conjugates, Phrontline Biopharma’s strategy is to tune the activity of each payload to a similar level and engineer both toxins to fit within a branched linker, its CEO tells Scrip in an interview.
If approved, VER-01 would be the first cannabinoid-based therapy for chronic low back pain.
After AI’s magic wand status, it's now come to Google and Open AI CEOs talking of the likelihood of a bubble burst. In this interview, Parexel’s India head discusses how to view returns on such investments, the CRO’s own use cases and the US FDA’s keenness on transparency and open dialogue.
The CEOs of two early-stage biotechs explain to Scrip why investor interest in ocular gene therapies is surging and how they aim to attract big pharma partners.
Meg Alexander is taking the place of founder Jeremy Levin, who is transitioning to executive chair, as Ovid prepares to move lead drug OV329 into a Phase IIa epilepsy study and generate initial data for its first-in-class KCC2 direct activators.
As pressure mounts to cut costs, reduce environmental impact, and accelerate development, pharmaceutical innovators are rethinking how medicines are made. A new generation of technologies—flow chemistry, biocatalysis, high-throughput experimentation (HTE), and advanced automation—is reshaping the fu
CEO Christophe Bourdon tells Scrip that the phone is ringing as the Danish drugmaker aims to become ‘the go-to partner for anything in dermatology.’
Five-year Agamree data shows the novel steroid is a safer and equally effective treatment to standard of care deflazacort or prednisone, the Swiss biotech argues.
Medicxi V marks the venture capital firm's biggest fund till date, raising its tally to six funds in the last decade, totaling over €2bn.